Antihypertensive treatment of patients with clinical manifestations of diabetic nephropathy, and especially, renin-angiotensin system (RAS) inhibition, slows, but may not fully arrest progression towards end-stage renal disease. Studies using 'hard' endpoints such as doubling of serum creatinine, dialysis, or death that are initiated before emergence of any renal functional abnormalities in diabetes, would be of impractical length and size. We therefore undertook a primary prevention study (The Renin-Angiotensin System Study or RASS) to determine if inhibition of the RAS could slow the development of a key diabetic glomerulopathy structural endpoint, increase in mesangial fractional volume (Vv[Mes/glom]).
Introduction
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the Western world and is responsible for approximately 45% of new ESRD in the United States. 1 This proportion has more than doubled in the last decade, mainly due to ESRD in patients with Type 2 diabetes mellitus (Type 2 DM). 2 Approximately 25% of patients with Type 1 diabetes mellitus (Type 1 DM) develop diabetic nephropathy, with renal failure occurring often after only 15-20 years, but sometimes as long as 40 or more years after onset. 2 Overt diabetic nephropathy is a late stage of a process that evolves histologically over years to decades, [2] [3] [4] and windows of therapeutic opportunity may close long before the disease is clinically evident. The demonstration that levels of albuminuria in a range not considered predictive of overt diabetic nephropathy may be associated with wellestablished renal lesions of diabetes 5, 6 raises the concern that initiation of treatment based on clinical markers may delay intervention until relatively late in the natural history of this disease.
Intensive glycaemic control may retard the progression of the long-term complications of diabetes, 7 and with return to euglycaemia after solitary pancreas transplant, established nephropathy lesions may even be reversed. 8 Although there was a 45% reduction in the development of microalbuminuria in patients treated with intensive glycaemic control for an average of 6.5 years in the Diabetes Control and Complications Trial (DCCT), 15% of the subjects developed nephropathy despite good control. 7 Moreover, the successes in the DCCT came at a high cost in terms of the need for frequent contact of participants by study personnel, a requirement for compliance with a complex regimen, increased weight gain and a consequent three-fold increase in severe hypoglycaemia. As shown in the DCCT follow-up study, the Epidemiology of Diabetes Intervention and Complications (EDIC), glycaemic control deteriorated in the intensive group patients when they returned to their usual care. 9 Thus, intensive treatment regimens are difficult to implement and, with the current therapeutic tools, optimal glycaemic control is difficult to achieve.
The role of the renin-angiotensin system (RAS) in the pathogenesis of diabetic nephropathy is supported by molecular, cellular and animal studies.The importance of the haemodynamic effects of angiotensin II (Ang II) on the renal microcirculation is well established. 10 Furthermore, the pivotal role of Ang II as a growth factor for the mesangial cell 11, 12 and for the production of renal extra-cellular matrix (ECM) has emerged. 13 Blockade of the RAS with angiotensin-converting enzyme (ACE) inhibitors or Ang II receptor blockers (ARBs) has become widely used in diabetic patients to slow the progression of established diabetic nephropathy. These agents are effective in reducing the time to doubling of serum creatinine, dialysis or death in Type 1 DM and Type 2 DM patients with overt diabetic nephropathy,at least in part, independent of systemic blood pressure (BP). [14] [15] [16] These drugs also retard progression from microalbuminuria to overt proteinuria in 'normotensive'Type 1 DM. 17, 18 However, it is not clear whether the beneficial effects of treatment with ACE inhibitors (ACE-I) or ARBs in overt diabetic nephropathy result from the modification of processes specific to diabetes, or result from nonspecific mechanisms that are common to many progressive renal diseases. 19 Moreover, cessation of longstanding ACE-I or ARB treatment in microalbuminuric diabetic patients may be associated with the appearance of proteinuria within weeks, 17, 20 suggesting that RAS blockade initiated at the stage of wellestablished diabetic nephropathy lesions may, in part, be clinically masking the progression of the diabetic renal pathologic processes.
The principal objective of this trial is to determine whether inhibition of the RAS can prevent or retard the development of the specific histological lesions of diabetic nephropathy in Type 1 DM patients without hypertension, microalbuminuria, or reduced glomerular filtration rate (GFR). Secondary outcomes include effects of treatment on renal functional endpoints and diabetic retinopathy (DR).This paper describes the design and recruitment of subjects for this trial.
Study methods Design
The Renin-Angiotensin System Study (RASS) trial is conducted at three centres: University of Minnesota (Minneapolis, Minnesota), McGill University (Montreal, Canada), and University of Toronto (Toronto, Canada). It is a randomised, double-blind, placebo-controlled clinical trial in subjects with Type 1 DM with three treatment arms: ACE-I (enalapril), ARB (losartan) or placebo; all subjects undergo a renal biopsy at baseline and after five years of treatment.The trial has received approval from the Food and Drug Administration (USA), Therapeutics Products Directorate (TPD) [formerly Health Protection Branch (HBP)] (Canada), and the institutional human research board at each centre. All participants have signed an informed written consent form after a detailed discussion of the study. The study follows Good Clinical Practice Guidelines. An External Safety and Monitoring Committee established by the National Institutes of Health (USA) annually reviews the study's progress. A Drug Monitoring Committee is regularly convened to review adverse events and medication side-effects.
Participants were randomised according to computer-generated blocks of six, with stratification by centre (Minnesota, Montreal,Toronto) and gender, into the following three treatment groups: 1) enalapril (ACE-I) 10 mg plus losartan (ARB) placebo once-daily; 2) losartan 50 mg plus enalapril placebo once-daily; or 3) enalapril and losartan placebos, once-daily. Approximately 40 months after randomisation of the first participant, and after about one-third of the total study drug exposure time had expired, data became available indicating that the magnitude of proteinuria reduction was greater on higher doses of ACE-I or ARB. 21 Consequently, the dose of each of the drugs was increased to 20 mg enalapril and 100 mg losartan by doubling the number of pills taken once per day.
Study subjects
Participants have Type 1 DM and no clinical evidence of diabetic nephropathy. Type 1 DM was defined as follows: onset was prior to the participant's 45th birthday. If the onset was between ages 31 and 40, body mass index (BMI) was required to be < 26 kg/m 2 at the time of diagnosis; if onset was between ages 41 and 45, a positive glutamic acid decarboxylase (GAD) or islet cell antibody (ICA) test was also required. In order to exclude patients at low risk of diabetic nephropathy, those without evidence of renal disease despite more than 20 years of diabetes 1, 22, 23 were not eligible to participate in the study.
Subject recruitment
Participants in RASS were recruited from two sources.The first was a group of subjects from the Minnesota and Montreal centres completing participation in the Natural History of Diabetic Nephropathy Study (NHS). 24, 25 The NHS was an observational study in which participants underwent a renal biopsy at the beginning of the study, were followed for five years and then a second renal biopsy was performed. For eligible NHS subjects, the exit NHS biopsy became the baseline biopsy for this trial. Patients exiting the NHS who had reached their sixteenth birthday were eligible for RASS. The second source of participants was from the diabetes clinics or offices of endocrinologists of the three collaborating centres, or subjects recruited from the local communities through advertising. Prospective subjects, eighteen years of age or older, who were not excluded based on the initial phone contact, were invited to come to the study centres for an initial screening interview. Upon arrival for this visit, the patient was provided with a copy of the informed consent form. After signing this form, the patient proceeded with eligibility testing. Consent forms were modified and resubmitted for approval whenever significant protocol changes were made, and study participants signed the new consent forms.
Eligibility screening
A series of pre-randomisation clinic visits were used to determine eligibility. Patients on any antihypertensive medications were excluded. BP was measured with a Dinamap monitor, and hypertension was defined according to published standards for Type 1 DM patients as BP > 135/85 mmHg. 26 Participants found to have a BP > 135 mmHg systolic or > 85 mmHg diastolic at the initial clinic visit had their BP re-measured on two additional occasions and were excluded if hypertension persisted. Patients with overt proteinuria (Dipstick ® positive) or with urinary albumin excretion rate (AER) > 20 µg/minute in two of three overnight urine collections were excluded. Patients avoided non-steroidal anti-inflammatory drug use during screening. Fasting blood samples were obtained for white blood cell count (WBC), serum electrolytes, haemoglobin A 1C (HbA 1C ), serum creatinine, and liver enzymes (ALT). Additional blood was obtained for DNA isolation and storage, and specimens of plasma and serum were saved at -70°C. Pregnancy tests were performed on all women of child-bearing age. If AER and blood pressure met study entry criteria, patients were given a two-week supply of pills (placebo).Those failing to take > 85% of these pills were excluded. Others then underwent measurement of GFR.
Clinical laboratory methods
The listed laboratory studies are all performed on materials sent to the central research laboratory at the University of Minnesota.
Kidney function studies
Glomerular filtration rate GFR is measured by plasma disappearance of nonradioactive iohexol. [27] [28] [29] Five ml of Omnipaque (300 mg iodine/ml), containing iohexol (3.235 gm) is injected into an arm vein, and after a two-hour waiting period blood samples are collected at +15 seconds of 120, 150, 180, 210 and 240 minutes from a venous catheter in the other arm. Iohexol plasma concentrations are determined by HPLC and iohexol clearance is first calculated according to a one-compartment model, corrected according to Brochner-Mortensen formula. 29 The GFR value then is normalised up to 1.73 m 2 .
Urinary albumin excretion rate AER is measured in timed overnight urine collections using a sensitive fluorescence immunoassay. 30 Patients with AER < 20 µg/minute in at least two of three consecutive urine samples are classified as normoalbuminuric (NA). Patients with AER > 20 but < 200 µg/minute in at least two of three consecutive samples are defined as having persistent microalbuminuria (MA), 1 while values > 200 µg/minute are considered as persistent proteinuria.
Haemoglobin A 1C (HbA 1C )
HbA 1C is measured using standard HPLC methods including the DIAMAT glycosylated haemoglobin analyser (BioRad, Hercules, CA) and the same lots of columns, resins and reagents. 24 Blood pressure studies Blood pressure BP is measured at baseline by trained observers using a Dinamap ® Vital Signs Monitor in a quiet setting after the patient is seated for five minutes. Three readings are taken one minute apart; the average of the second and third readings is used. If the patient is hypertensive (HT) BP is reassessed within two weeks and, if still present, again in a further two weeks. If HT is present at the 3rd assessment, anti-HT therapy is initiated.
Ambulatory blood pressure monitoring (ABP)
Twenty-four-hour ABP monitoring is performed using the SpaceLabs 90207 monitor (Redmond Washington). BP is recorded at 20-minute intervals day and night for a period of 24 hours and individual measurement values analysed.
Renal biopsy procedure
Baseline renal biopsies were performed by the senior study nephrologists at each site after all inclusion criteria were satisfied.At the time of biopsy, participants had normal BP, coagulation studies and platelet counts. Kidneys were localised by ultrasound, which was also used to determine renal size. Standard percutaneous renal biopsy techniques were used based on the G14 Franklin modified Vim-Silverman, G16 Truecut ® needles or the G16 Biopty ® needle. Patients received pre-biopsy sedation if requested.The biopsy specimens were immediately examined and divided under a dissecting microscope 5 to ensure adequate samples for electron microscopy (EM) analyses and light microscopy (LM).Availability of two glomeruli for EM studies was an entry criterion, and the renal biopsy was repeated if necessary. If additional tissue was available, it was prepared for immunofluorescent microscopy, 31 immunogold EM, 32 and tissue culture for ancillary studies.A skin biopsy was obtained at the time of the renal biopsy at the renal biopsy site with a 3 mm punch biopsy and was immediately placed in culture medium for ancillary studies.
Renal morphometric measures
Tissue for electron microscopy (EM) is fixed in 2.5% glutaraldehyde in Millonig's buffer, transported to the Minneapolis centre, and processed for electron microscopy, as previously described. 5 Tissue for light microscopy (LM) is fixed in Zenker's solution and embedded in paraffin. 5 Three LM slides are cut at each study centre for rapid pathology examination and reporting. The remainder of the LM block is sent to the Minneapolis center, cut completely into 5 µm sections, and all sections are saved, sequentially numbered, and stained with periodic acid Schiff (PAS).
Retinopathy studies
Pupils are dilated and 30º stereoscopic colour fundus photographs are taken of the seven standard fields, as defined in the Early Treatment Diabetic Study (ETDRS) protocol. 33 The photographs are graded in a masked fashion at the University of Wisconsin Ocular Epidemiology Reading Center using the same modified Airlie House Classification scheme 34, 35 and the ETDRS classification scheme for assigning severity of DR that was used at baseline. 36 Participants are instructed to have annual eye examinations with their private optometrist/ophthalmologist.
Compliance
Methods to maximise compliance to study procedures and to medications are standardised across the centres. They include newsletters, social and informational sessions, cards recognising birthdays or other significant milestones, pill minders and mid-visit telephone calls.
Longitudinal follow-up
All participants are seen every three months (+ three weeks) by the local study coordinator, with visit dates determined by the date of medication initiation. The diabetes management is under the supervision of the patient primary care physician or specialist.The clinical centres record the number of insulin injections, type of insulin, and the amount of insulin administered. Serum potassium and serum creatinine are measured two weeks after starting the study medication and after the dosage increase to detect increased levels. At each visit, the following is performed: interim health history (including medications and adverse events), participant selfassessment of drug compliance, confidential pill count, measurement of weight, height and BP, AER on an overnight urine collection, HbA 1C , a pregnancy test for women of child-bearing age, and a session with the Trial Coordinator to maintain and improve medication compliance. At the quarterly visits, participants return the unused medication and are provided with a new three-month supply of study medications. Participants are contacted by phone every 2-4 weeks during the first three months after randomisation and at mid-point intervals between visits for the remainder of the study. These phone calls are used as reinforcement for medication compliance and to inquire about adverse events or other study-related issues.
At each annual visit, a more complete assessment is performed, including the GFR, 24-hour ABP, documentation of current insulin regimen, assessment of exercise patterns, changes in socioeconomic status, pregnancy tests on women of child-bearing age, serum potassium, serum creatinine, WBC, ALT, and saved blood and urine specimens. Plasma for renin measurements were obtained prior to the increase in study medication and repeated at three months and again at 12 months following the increase in study drug dosage. Plasma renins are drawn again at the fiveyear biopsy and two months after medication discontinuation, at the conclusion of the study.
Retinal photographs are obtained at baseline and at the mid-point and conclusion of the study. At the study conclusion, an exit renal biopsy is obtained. Two weeks after subjects have discontinued their study medications, i.e. following the exit biopsy visit, the BP is checked.At a one-month post-biopsy visit, an overnight urine for AER is collected and the BP is checked.At two months postbiopsy, measurements are obtained of BP, AER, plasma renin, GFR and ABP monitoring.
Hypertension
When systolic BP > 135 mmHg or diastolic BP > 85 mmHg is detected at a clinic visit, the partici-pant returns to clinic in two weeks for a second measurement. If hypertension persists, BP is checked again two weeks later. If the BP again remains elevated, treatment is initiated to reach a target BP of < 130/85 mmHg. The choice and order of the following drugs is at the discretion of the investigator: i) diuretics (hydrochlorothiazide or indapamide), ii) calcium channel blockers (amlodipine, diltiazem, verapamil); iii) central α-blockers (clonidine or alphamethyldopa); iv) peripheral α-blockers (prazosin); or v) β-blockers (acebutolol). If the target blood pressure is not achieved with these medications, a meeting of the Drug Monitoring Committee is convened. If this committee determines that RAS blockade is warranted, a study pharmacist substitutes enalapril for the enalapril placebo in the group of patients taking double placebos. Those patients on losartan and enalapril groups do not have their study medications altered. The investigators will manage antihypertensive therapy and these participants will continue to follow the study protocol.
Increasing AER
The study personnel are blinded to the post-randomisation AER data. However, centres are informed when AER exceeds 150 µg/minute. If confirmed on two additional urine samples spaced six weeks apart, the study medication is discontinued. At one and two months following discontinuation of study medication AER is re-measured, and at two months the GFR is re-measured. At this point a study pharmacist substitutes enalapril for the enalapril placebo in the group of patients taking double placebos.The losartan and enalapril groups do not have their study medications altered.
Pregnancy
Females of child-bearing age are reminded at each clinic visit of the potential adverse effects of the study drugs on fetal outcome and are instructed to report missed menstrual periods immediately. Pregnancy tests are administered at the quarterly visits.When pregnancy is suspected or detected the study drugs are immediately withheld until pregnancy is ruled out, completed or terminated. Kidney function tests and renel biopsy are postponed until at least 12 weeks postpartum. Medications are also withheld while the mother breastfeeds her baby.
Intercurrent illness or adverse event
An adverse event form is completed at each clinic visit or for any adverse event occurring between clinic visits. Each serious adverse event considered to be a possible medication side-effect is reviewed within 24 hours by the Drug Monitoring Committee. The patient's primary physician manages intercurrent medical problems.
Statistical analysis and sample size justification
The principal outcome variable is the annual rate of change (r) of mesangial fractional volume per glomerulus (Vv[Mes/glom]) over the five years of the study, as determined from the baseline and five-year exit biopsies. The first step will be to assess the variability of r explained by background factors such as the initial Vv(Mes/glom), duration of disease as of first biopsy, age at onset, sex, etc., and by various explanatory factors under study, namely HbA 1C , BP, GFR, etc., measured within the interval spanned by the two biopsies. Multiple linear regression will be used for this step.
The next step will be to compare the two treatment groups under study (enalapril, losartan) with placebo. Multiple linear regression will be used to estimate mean differences in r and the corresponding confidence intervals.These analyses will be repeated for GFR and albuminuria.
A minimum of 95 patients is required per group (285 in total) to assess the primary hypothesis of the study.The sample size is based on the primary method of analysis, namely linear regression, and the primary outcome variable, Vv(Mes/glom), with assumptions about its distribution originating from 21 patients completing the NHS 24, 25 and meeting all the eligibility criteria for the current study.The data on these patients indicated that the mean rate of change (r) over five years is 0.0533 (SD = 0.0684; range -0.06 to 0.19).A simple linear regression of r on the initial Vv(Mes/glom) shows that 27% of its variance is explained by this initial Vv(Mes/glom). Extending this analysis to a multiple linear regression model containing the initial Vv(Mes/glom), HbA 1C , GFR and diabetes duration, the variance explained increased to 35%.Thus, the standard deviation was reduced from its crude value of 0.0686 to 0.0557.Assuming that homogeneity of these factors will be greater in the trial, we can safely assume an adjusted standard deviation of 0.0557 for the change in Vv(Mes/glom).
The estimate sample size requirement is based on an overall two-sided significance level of α = 5% and a power of 80% (β = 20%). This is reduced to α = 2.5% by a Bonferroni adjustment, which is necessary because of the two contrasts for the primary hypothesis of interest: losartan versus placebo and enalapril versus placebo.
By applying the assumption that the annual rate of change (r) Vv(Mes/glom) can be reduced by 50% (i.e. from the expected 0.0553 to 0.0267), the trial requires 95 patients per group or 285 in total, respectively, allowing for a 10% drop-out rate. Finally, if the two contrasts indicate a similar magnitude, the two treated groups (losartan and enalapril) will be combined into one and contrasted with placebo to increase power. Secondary analyses will examine additional renal structural and renal functional endpoints.
Since other studies suggested that RAS blockade slowed progression of diabetic retinopathy, we are performing baseline, mid-point and fiveyear fundus photography. 36 However, the sample size determination for RASS was based on changes in Vv(Mes/glom) over five years, and the RASS trial may not have adequate statistical power to detect small effects of RAS blockade on DR.
Results

Recruitment and randomisation
A total of 1,065 potential participants were identi-fied at the three centres; 707 refused participation, and 73 failed to meet the inclusion criteria. The target total of 285 subjects were enrolled and randomised: 96 from Minnesota, 95 from Montreal and 94 from Toronto. There were no significant differences in age, age at onset of diabetes, duration of diabetes, or gender among patients refusing participation and those who were randomised ( Table 1) .
The baseline characteristics are summarised by study and by centre in Table 2 . The age was 30.5+9.8 years (X+SD). The age of diagnosis of Type 1 DM was 18.8+10 years, and the duration of diabetes at time of entry into the study was 11.3+4.7 years. Almost all patients (97.9%) were Caucasian. Modest, but significant, baseline differences among the centres were observed in age, age at diagnosis of diabetes, BMI, BP, GFR, and serum creatinine. The Toronto centre patients tended to be older and have a later age of onset, with the youngest mean age and age of onset in Montreal. As a probable age effect, systolic and diastolic BP were highest in the Toronto group. Consistent with our findings in NHS, 24 although by selection GFR was always in the normal range, the mean group values tracked inversely with age, consistent with less hyperfiltration in the older patients, despite similar duration and glycaemia. There were also no group differences for gender or AER.
Biopsy adequacy and complications
Three subjects required a repeat biopsy due to initially inadequate tissue to meet the inclusion criteria. Biopsy complications were seen in 17 (6.0%) of the participants.These included, transient gross haematuria in eight patients, transient post-biopsy pain in five, small perinephric haematoma in four, nausea in three patients and one patient with temporary bladder obstruction due to clots.The only serious complication was a large peri-renal haematoma and gross haematuria requiring hospitalisation for five days with supportive therapy but no further intervention. This subject withdrew consent and was not randomised.
Discussion
The successful recruitment and randomisation of the study cohort demonstrates the feasibility of performing diabetic nephropathy prevention studies based on a renal structural outcome. The PAPER recruitment rate for this study (28.7%) is virtually identical to the rate previously reported for the North American centres in the NHS. 24 We believe the high rate of recruitment, despite the demanding tasks of the study, is related to the widespread awareness of the adverse effects of diabetes on the kidney as well as the perceived potential for the treatment to reduce the risk of nephropathy. The participants in this study appear to be representative of the general Type 1 DM diabetic population, since no significant demographic differences were observed between the randomised and non-randomised subjects. Centre differences were observed for some demographic factors (age and age of diagnosis) and age-related variables (BMI, BP), but stratification by centre should account for these differences in the randomisation process. Moreover, specific diabetes-related variables (duration, HbA 1C ) were not significantly different in the three centres. The use of a renal structural (i.e. biopsy) outcome is particularly valuable in slowly developing renal diseases such as diabetic nephropathy and hypertensive nephrosclerosis, since these account for the vast majority of patients with ESRD. 1, 37 Progressive renal structural injury in these disorders develops over years to decades before measurable clinical and laboratory abnormalities, such as proteinuria or declining GFR, become evident. 1, 37 The earliest clinical manifestations of diabetic nephropathy often represent already well-established renal injury. 1, 5, 6, 23 Thus, microalbuminuria, currently the best clinical indicator of increased risk for diabetic nephropathy, may be associated with lesions that are so advanced as to overlap with lesions seen in patients with overt proteinuria and declining GFR. 5, 6 This may very well account for the observation that established therapies, in the main, only slow the progression of diabetic nephropathy. [14] [15] [16] Waiting for clinical or laboratory signs of renal disease to emerge before initiating treatment could compromise the effectiveness of treatment in preventing progression to ESRD. Unfortunately, given the long natural history of diabetic nephropathy, evaluation of treatment interventions at pre-clinical stages using a 'hard' renal functional outcome such as declining GFR, dialysis, or death, would lead to trials of such duration and sample size as to be completely impractical. 37 Study duration was based on results from the NHS indicating the Vv(Mes/glom) changes over five years are adequate to test the study's primary hypothesis with a study cohort similar in size to that recruited for the NHS study. A positive outcome from this study has great potential to alter treatment regimes and reduce morbidity in Type 1 DM and to change treatment trial designs in chronic renal diseases.
The design of this study, based on histopathological changes determined from paired renal biopsies spaced five years apart, will show whether inhibition of RAS activity can retard or prevent the specific lesions of progressive diabetic renal disease. Change in Vv(Mes/glom) was selected as the primary endpoint because of prior observations in both Type 1 DM 1,3-6 and Type 2 DM 38-40 indicating a strong association with clinical manifestations of diabetic nephropathy.
Thus, mesangial expansion is associated directly with AER, BP, and inversely with GFR in Type 1 DM 1,3-6 and Type 2 DM, [38] [39] [40] and predicts GFR decline in Type 2 DM. 40 Change in Vv(Mes/glom) is associated with change in AER in longitudinal biopsy studies in Type 1 DM patients. 41 However, Vv(Mes/glom) does not account for all of the variability in AER and GFR, 6 and other structural changes, including glomerular basement membrane width, 6 cortical interstitial fractional volume, [42] [43] [44] [45] [46] % glomerular sclerosis 47 or % atubular glomeruli 48 may also contribute to renal dysfunction in diabetic nephropathy. To account for this possibility, secondary analyses incorporating multiple structural parameters using a composite structural index will be performed. In addition, since ACE-I and ARB therapy both inhibit the RAS, we will also carry out secondary analysis combining the two treatment groups for comparison with the placebo group. Renal functional outcomes will also be assessed, but it is anticipated that the size of patient enrolment and duration of the study will limit the power to identify clinical effects.
Agents that inhibit RAS activity may be particularly useful in preventing diabetic nephropathy. Elevated levels of plasma prorenin are associated with increased risk of diabetic nephropathy, 49 and elevated plasma total renin or prorenin precedes the development of microalbuminuria. 50 It has been suggested that TGF-β is pivotal in the extracellular matrix accumulation that is central to diabetic nephropathy. 51 High ambient glucose appears to increase mesangial cell Ang II production, 52 stimulating the glucose transporter 53 and protein kinase C systems, 54 resulting in TGF-β activation and extracellular matrix accumulation.Ang II also upregulates TGF-β receptor expression and TGF-β fibrogenic actions. 11 These in vitro effects of Ang II can be blocked by losartan 55 and by saralasin, 13 an Ang II competitive inhibitor. Diabetic rats with deficient Ang II Type 1 receptors do not have increased renal TGF-β mRNA levels. 56 Finally, intraglomerular influences of the RAS in diabetes could result in glomerular capillary hypertension, 57 mechanical stretching of mesangial cells 58 and consequent stimulation of the TGF-β system.
Several previously reported studies support the conclusion that RAS blockade reduces the rate of progression of proteinuria to ESRD. [14] [15] [16] However, diabetic patients with proteinuria already have advanced diabetic nephropathy lesions; 1,3,6 at these late stages, RAS blockade may interfere with forces common to many advanced renal diseases and not specific to diabetic nephropathy. 19 This study will test the hypothesis that RAS blockade can interfere with the genesis of the early and specific lesions of diabetic nephropathy. If true, this would go a long way to proving the role of the RAS in the pathophysiology of diabetic nephropathy and argue for preventive treatment with drugs that block the RAS in all Type 1 DM patients.
